natgillin/translations-raw huggingface dataset:
Disclosed is a method that includes obtaining a biological sample from a subject (e.g., plasma, serum, blood, urine, or cerebrospinal fluid), contacting the sample with highly purified viral-like particles (HPVLPs) under conditions suitable for binding of a JCV antibody in the sample to an HPVLP, and detecting the level of JCV antibody binding in the sample to HPVLP. 
PATENTNI ZAHTJEVI Postupak in vitro, naznačen time što se sastoji u: (a) stavljanju u kontakt biološkog uzorka dobivenog iz subjekta s visoko pročišćenim česticama sličnim virusima (HPVLP-i), koje se pretežno sastoje od proteina VPI iz virusa JC (ICV), u otopini u uvjetima pogodnim za vezanje protutijela protiv JCV u uzorku na HPVLP, čime se dobiva predinkubiran uzorak;
(xxii) a heteroaryl group optionally substituted by one or more substituents selected from the group consisting of a halogen atom, a hydroxyl group, a C1-6 alkyl group, and —ORa21 (where Ra21 represents a C1-6 alkyl group), or 
(xxii) heteroaril skupinu proizvoljno supstituiranu sa jednim ili više supstituenata odabranih iz skupine koja sadrži atom halogena, hidroksil skupinu, C|.g alkil skupinu, te -OR"! (gdje R*! predstavlja C;.4 alkil skupinu), ili
• A and B are selected independently from CH and N with the proviso that A and B are not both N at the same time 
QjeNH * A1Bse izabiru nezavisno između CH 1 N uz uvjet da A 1 B nisu oba N u isto vrijeme *
Process according to claim 1, further comprising the following steps for preparing compound (3): activation of 6-methyl-2-benzo[b]thiophenecarboxylic acid of formula (1) 
Postupak prema patentnom zahtjevu 1, naznačen time da dalje obuhvaća sljedeće korake za pripravu spoja (3): a) aktivacija 6-metil-2-benzo[b]tiofenkarboksilne kiseline formule (1)
With reference to Figure 1, in one aspect of the invention, an apparatus and process combines a high volume of air delivered to the crop and a low volume metering of the additive (e.g. a mixture of biologically active or chemical substance and water) into the stream of air to carry and distribute the additive into a crop. 
S pozivom na sliku 1, prema jednom vidu izuma, uređaj i postupak kombiniraju veliku količinu zraka usmjerenu na usjev i malu količinu doziranog aditiva (na primjer smjese biološki aktivne ili kemijske supstance 1 vode) u struju zraka da ponese i raspodijeli aditiv u neki usjev.
Chromatographic profile by HPLC-RP obtained during the quantification of the residual glutaraldehyde content of the vaccine composition obtained by the purification method using 50 kDa ultrafiltration membranes (vaccine composition A) and for the vaccine composition using dialysis purification method (vaccine composition B). 
Postupak za dobivanje sastava cjepiva prema zahtjevu 12, naznačen time, da se konjugirani protein purificira metodom ultrafiltracije/dijafiltracije uporabom membrane koja ima veličinu pora od 50 kDa ili 100 kDa.
More usually, the porous layer comprises mesoporous TiO2. Often, the porous layer of an n-type semiconductor is in contact with a compact layer of an n-type semiconductor. Usually, the compact layer of an n-type semiconductor comprises oxide of titanium, tin, zinc, niobium, tantalum, tungsten, indium, gallium, neodinium, palladium or cadmium, or a mixture thereof. 
(c) materijal za prijenos naboja, koji je materijal za prijenos šupljina; po izboru, pri čemu porozni sloj poluvodiča n-tipa sadržava: oksid titana, kositra, cinka, niobija, tantala, volframa, indija, galija, neodiniuma, paladija ili kadmija, i poželjno sadržava TiO> i po izboru, kada je porozni sloj poluvodiča u kontaktu s kompaktnim slojem poluvodiča n-tipa, a poželjno je da kompaktni sloj poluvodiča n-tipa sadržava TiO».
The invention also provides the use of IL-2 microaggregates of the invention in the manufacture of a medicament, wherein the medicament is co-administered with a second pharmaceutical agent. 
Izum također daje uporabu IL-2 mikroagregata iz izuma u proizvodnji medikamenta, kod čeka se medikament usporedo daje s drugim farmaceutskim agensom.
A pharmaceutical formulation for the treatment of cell differentiation and proliferation-related diseases, which is characterized in that the pharmaceutical formulation comprises the chidamide crystal form A according to claim 1, and pharmaceutically acceptable excipients. 
Farmaceutski pripravak za korištenje u liječenju bolesti vezanih uz staničnu diferencijaciju 1 proliferaciju, koji je naznačen time što farmaceutski pripravak sadrži kristal kidamida oblika A u skladu sa zahtjevom 1 i farmaceutski prihvatljive pomoćne tvari.
In like manner to that described in Example 7 A, B and E and Example 15 D, the named compound (cis-racematel was prepared from commercially available 4-bromobenzophenone (m.p. 
Cis-(1SX(1R)-N-metil-4-(4-bromofenil)-1,2,3,4-tetrahidro-1-naftalinamin klorhidrat Na sličan način s onim koji je opisan u primjeru 7A, B1E i primjeru 15 D, napravljen je imenovani spoj (cis-racemat) iz komercijalno pristupačnog 4-bromoacetofenona (tt.
is selected from hydrogen and halogen; 
R' se bira iz vodika i halogena
This lever 115 is made by press-forming or machining so as to feature a rather substantial thickness and, as viewed laterally from the top down, includes: an upper portion 120 featuring an upward concave contour, and a first bore 115 located in the widening zone 116 of the box-like accommodation 112, intended to receive the hinging pin 127 (visible in FIGS. 5 and 6) for the same lever 114; an intermediate portion provided with a rearwards protruding wing 117, where a second bore 118 of the lever 114 is provided; a lower portion that terminates in a punch 119 . 
Ova poluga 115 načinjena je prešanjem ili strojnom obradom, tako da je prilično debela, te, kada je se promatra sa strane odozgo, sadrži: gornji dio 120, uspravljene konkavne kontoure, te prvi provrt 115, smješten u širećoj zoni 116 kutijastog uređaja 112, namijenjen za umetanje zatika za uzglobljenje 127 (vidi se na Slikama 5 1 6) iste poluge 114; međudio opremljen je krilom 117, koje se pruže prema straga, gdje se nalazi drugi provrt 118 u poluzi 114; donji dio koji završava probijačem 119.
is OH; Y is O; and R2 is a pyridyl ring being optionally substituted by cyano or halogen. Definitions 
R1 je OH; Y je O; i R2 je piridil-prsten koji je opcijski supstituiran sa cijano ili halogenom.
The chemically modified glycosaminoglycans according to claim 3, wherein the modified glucosamines are presented as signals at 5.95 ppm and 6.15 ppm in an 1H-NMR spectrum. 
4. - Kemijski modificirani glikozaminoglikani prema zahtjevu 3, naznačeni time da se modificirani glukozamini nalaze kao signali na 5,95 ppm i 6,15 ppm u IH-NMR spektru.
Q is selected from the group consisting of phenyl, pyridyl, thiazolyl, thiophenyl, pyrimidyl, each optionally substituted with one or two groups independently selected from the group consisting of C1-6alkyl, halo-C1-6 alkyl, halogen and CF3; 
Q je izabran iz grupe koja se sastoji od fenil, piridil, tiazolil, tiofenil, pirimidil, svaka izborno supstituirana sa jednom ili dvije grupe nezavisno izabrane iz grupe koja se sastoji od C1-6alkil, halo-C1-6 alkil, halogen i CF3;
at least one bulking agent at a final concentration from about 1.5% to about 5% w/v or 
najmanje jedno punilo u konačnoj koncentraciji od oko 1.5% do oko 5% tež./vol. ili
The method of para 20, wherein the optional reagent added together with hydrogen peroxide prior to concentration of the reaction mixture is selected from sodium acetate, sodium butyrate, and sodium salts of alpha-hydroxy acids. 
Postupak prema zahtjevu 14, naznačen time da je proizvoljni reagens koji se dodaje zajedno s vodikovim peroksidom prije koncentriranja reakcijske smjese odabran od natrijevog acetata, natrijevog butirata, i natrijevih soli alfa-hidroksi kiselina, ili od kalijevog acetata, kalijevog butirata, i kalijevih soli alfa-hidroksi kiselina.
A method for modulating the growth of a plant and/or germination of a seed comprising contacting said plant, its growth substrate, and/or a seed of said plant with an amount of a composition comprising: (a) a supernatant, or cell fraction collected from Bacillus strain F727, NRRL Accession No. 
Postupak za modulaciju rasta biljke ili klijanje sjemena koji sadrži kontakt s biljkom i njen supstrat rasta ili sjeme navedene biljke s količinom spoja sukladno zahtjevima 1-2, učinkovitog za modulaciju rasta navedene biljke ili klijanje navedenog sjemena.
In this case it is sufficient that the relay location performs the detection of the second phase relation between the wiring phase at the relay location and the newly added remote location. 
- < otkrivanje drugog faznog odnosa između faznog napona vodiča na spomenutoj relejnoj lokaciji i faznog napona vodiča na spomenutoj udaljenoj lokaciji;
The method of claim 1, wherein the polypeptide binds to GDF 11 . 
Polipeptid za uporabu prema zahtjevu 5, pri čemu je kemoterapijski tretman taksan.
R2b and R2c are independently selected from the group consisting of hydrogen, halogen, C1-C3 alkyl, fluorinated C1-C3 alkyl, cyano, C1-C3 alkoxy, and N(CH3)2; X is selected from the group consisting of 
R3 je neovisno odabrana iz skupine koju čine halogen, C;-Cz alkil, fluorirani C,-C3 alkil, cijano, Cy-C3 alkoksi 1 NR+4Rx, gdje R4 i Ry su neovisno odabrane iz skupine koju čine
An inhaler according to claim 1, wherein the unitary component further defines a mouthpiece arranged to receive, in use, the entrained medicament from the air outlet of the manifold. 
Inhalator u skladu s bilo kojim prethodnim patentnim zahtjevom, pri čemu jedinstvena sastavnica nadalje određuje dio za usta (133) postavljen da prihvaća, u uporabi, uneseni lijek iz izlaza zraka (129) cjevovoda.
Pellets according to claim 3, wherein the total amount of the potassium chloride and sodium chloride is 20 to 60% by weight. 
Granule sukladno patentnom zahtjevu 3, naznačene time što je ukupna količina kalijeva klorida i natrijeva klorida 20 do 60% (težinski).
wherein n is chosen from integers ranging from 1 to 10, P is chosen from amino protecting groups, and Y is a second reactive group; and 
Formula II pri čemu n je odabran od cijelih brojeva u rasponu od 1 do 10, P je odabran od amino zaštitnih skupina, i Y je druga reaktivna skupina; i
A glove stacking apparatus (101) as claimed in Claim 1, in which said means to apply said vacuum air pressure comprises at least one perforation (91) in a work surface (164) beneath the permeable surface of the movable flap (171,173). 
Uređaj (101) za slaganje rukavica u skladu s patentnim zahtjevima 2 ili 3, u kojima je navedeno udubljenje u rukavci (162) za pakiranje umetnuto u radninu površinu (164).
A packaging method according to claim 1, wherein the polylaminate that seals the top of the cup-shaped body in step (b1.5) comprises a first layer made of polyethylene terephthalate modified with EVOH, a second layer made of polyethylene terephthalate and a third layer made of polypropylene. 
Postupak pakiranja u skladu s patentnim zahtjevom 1, naznačen time, da polilaminat koji brtvi vrh kućišta u obliku čaše u koraku (b1.5) sadržava prvi sloj izrađen od polietilen tereftalata modificiranog s EVOH, drugi sloj izrađen od polietilen tereftalata i treći sloj izrađen od polipropilena.
A compound according to any one of the preceding claims wherein R14 is selected from a heterocyclic or heterocycloalkyl group selected from the group consisting of: 1,3-dioxolane, 2,2-dimethyl-1,3-dioxolane, thiophene, 1-methyl-1-morpholino-4-ylethyl, pyrimidine, pyridine, said pyridine optionally substituted with a hydroxy or C1-C6 alkoxy group; pyridinyl-linear or branched C1-C4 alkyl; piperidine, said piperidine optionally substituted with phenyl-C1-C4 alkyl; furane, tetrahydrofurane; 2-tetrahydrofuran-2-ylethyl, pyrrolidine N-carboxylic acid, C1-C4 linear or branched N-alkoxycarbonylpyrrolidin-2-yl; tetrahydopyrane. 
Spoj prema bilo kojem od prethodnih zahtjeva naznačen time da R'' je odabran od heterocikličke ili heterocikloalkilne skupine odabranih iz skupine koju čine: 1,3-dioksolan, 2,2-dimetil-1,3-dioksolan, tiofen, 1-metil-1-morfolino-4-iletil, pirimidin, piridin, navedeni piridin proizvoljno je supstituiran sa hidroksi ili C,-C4 alkoksi skupinom; piridinil-ravni ili razgranati C;-Ca alkil; piperidin, navedeni piperidin proizvoljno je supstituiran sa fenil- C,-C, alkilom; furan, tetrahidrofuran; 2-tetrahidrofuran-2-iletil, pirolidin N-karboksilna kiselina, C,-C, ravni ili razgranati N-alkoksikarbonilpirolidin-2-il; tetrahidopiran.
The isolated antibody or fractalkine-binding fragment thereof of claim 5, wherein the antibody comprises a heavy chain and a light chain, wherein the heavy chain variable domain of said antibody comprises the amino acid sequence of SEQ ID NO: 26, and wherein the light chain variable domain of said antibody comprises the amino acid sequence of SEQ ID NO: 27. 
Protutijelo ili njegov fragment koji veže fraktalkin prema zahtjevu 4, naznačeno time što protutijelo sadrži teški lanac i lagani lanac, pri čemu varijabilna domena teškog lanca navedenog protutijela sadrži sekvencu aminokiseline iz SEQ ID NO: 26, i pri čemu varijabilna domena laganog lanca navedenog protutijela sadrži sekvencu aminokiseline iz SEQ ID NO: 27.
N = total number of subjects 
Broj međunarodne objave:
Pharmaceutical composition or dosage form a for use of claim 38, wherein said crystalline trans-(±)-A9-THC is delivered to the lungs of said mammal from a mechanical device suitable for pulmonary administration and capable of depositing said crystalline trans-(±)-A9-THC of a mammal, preferably selected from the group consisting of powder inhaler, a unit dose inhaler, a metered dose inhaler, a pump spray and a nebulizer. 
Farmaceutski sastav ili oblik doziranja za upotrebu prema zahtjevu 38, naznačen time je navedeni kristalni trans-(±)-A9-THC dostavljen u pluća navedenog sisavca iz mehaničkog uređaja pogodnog za plućnu primjenu i sposobnog za dostavljanje navedenog kristalnog trans-(±)-A9-THC sisavcima, koji je poželjno odabran iz grupe koja sadrži inhalator praška, inhalator koji sadrži jediničnu dozu, inhalator s brojačem doza, sprej pumpicu i nebulizator.
The door handle assembly according to claim 1, wherein said flexible connector is chosen from group consisting of at least one helical spring, and at least one elastic band. 
Sklop ručke vrata sukladno bilo kojem od prethodnih patentnih zahtjeva, naznačen time što je navedeni spojni element (3) odabran iz skupine koja sadrži spiralnu oprugu, elastičnu vezu.
A compound as claimed in claim 13, for use when the pain disorder is neuropathic pain or fibromyalgia. 
Spoj u skladu s patentnim zahtjevom 28, naznačen time, da je poremećaj boli neuropatska bol ili fibromijalgija.
a second texturing agent comprising xanthan gum, a mass ratio of the mannoproteins to the xanthan gum is 1:4 to increase a texturizing effect of said xanthan gum, the topical composition comprising 0.2% mannoproteins and 0.8% xanthan gum based on a total weight of said topical composition, and 
Uporaba, u kozmetičkim i/ili dermatološkim sastavima, manoproteina izdvojenih iz staničnih stijenki gljivica kao teksturirajućeg agensa s ksantanskom gumom kao drugim teksturirajućim agensom, maseni omjer manoproteina prema ksantanskoj gumi je sadržan između 1:5 i 1:3.
Accordingly, the invention provides a pharmaceutical composition for use in a method of preventing or treating malaria, said composition comprising: artemether or arteether; and a pharmaceutically-acceptable excipient selected from the group consisting of: medium chain length triglycerides; short chain triglycerides; omega-3-marine triglycerides and fish oil, rich in omega-3-acids, said composition formulated for transmucosal sublingual, buccal or nasal dosage. 
HR P20140773 T1 PATENTNI ZAHTJEVI Farmaceutska kompozicija naznačena time što sadrži: artemetar ili arteetar; 1 farmaceutski prihvatljiv inertni punitelj izabran 1z grupe koju čine: triglideridi srednje dužine lanca; trigliceridi kratkog lanca; omega-3 trigliceridi porijeklom iz mora; i riblje ulje, bogato omega-3-kiselinama pri čemu je navedena kompozicija formulirana za transmukozalnu subligvalnu, bukalnu ili nazalnu dozu.
The method of any one of claims 19 to 22, wherein the antigen is an influenza virus antigen; for example, wherein the combination of the emulsion and the antigen forms a vaccine composition which includes about 15µg, about 10µg, about 7.5µg, about 5µg, about 3.8µg, about 1.9µg, about 1.5µg of hemagglutinin per influenza virus strain 
Postupak prema bilo kojem od zahtjeva 19 do 22, naznačen time da antigen je antigen virusa gripe; na primjer, postupak, naznačen time, što kombinacija emulzije i antigena formira sastav cjepiva koji uključuje oko 15ug, oko 10ug. oko 7.5ug, oko 5ug, oko 3.8ug, oko 1.9ug, oko 1.5ug hemaglutinina po vrsti virusa gripe
The use according to claims 5 to 7, wherein the calcitonin mimetic is for use in treating osteoporosis or osteoarthritis. 
Mimetik kalcitonina za za primjenu sukladno patentnom zahtjevu 2, pri čemu je mimetik kalcitonina za primjenu u liječenje osteoporoze ili osteoartritisa.
providing a fresh cylinder oil from a fresh cylinder oil storage compartment, and blending the used oil with the fresh cylinder oil in a blending apparatus, wherein the used oil has a lower TBN value than the fresh cylinder oil and wherein the cylinder oil and the fresh cylinder oil are all-loss cylinder oils for use in crosshead diesel engines and comprise alkaline additives. 
- osiguravanje rabljenog ulja, - osiguravanje svježeg cilindarskog ulja, i - miješanje rabljenog ulja sa svježim cilindarskim uljem, naznačen time da rabljeno ulje ima nižu TBN vrijednost nego svježe cilindarsko ulje i pri čemu su cilindarsko ulje i svježe cilindarsko ulje cilindarska ulja iz sustava s totalnim gubitkom ulja za uporabu u dizel motorima sa križnom glavom i sadrže alkalne aditive.
Schizophrenia is associated with dopamine imbalances in the brain and defects of the frontal lobe and is caused by genetic and other biological factors and psychosocial factors. 
Å izofrenija je povezana sa poremećenim balansom dopamina u mozgu i oštećenjem u prednjem dijelu te je uzrokovana genetskim i ostalim biološkim psihosocijalnim čimbenicima.
The method of claim 1, wherein the bag (20) is filled with a sample through an aperture (25, 26), the aperture is sealed and the sample in the bag is frozen. 
(20) stavlja kroz otvor (25, 26), zatim se otvor hermetički zatvara,a a uzorak u navedenoj vrećici se zamrzava.
Identification and optimization of HLA-A*2402 restricted tumor cryptic peptides is therefore necessary for developing efficient cancer vaccines for HLA-A*2402 expressing patients. 
Metoda za dobivanje HLA-A*2402-restrikcijskog epitopa koji može potaknuti imuni odgovor protiv HLA-A*2402 restrikcijskog kriptičkog epitopa antigena, obuhvaća korake
The method of any of the preceding claims, wherein desPro36Exendin-4(1-39)-Lys6-NH2 or/and a pharmaceutically acceptable salt is administered in an add-on therapy to administration of metformin and insulin glargine. 
Kombinacija namijenjena upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što se dezPro**Eksendin-4(1-39)-Lyss-NH, ili/i njegova farmaceutski prihvatljiva sol primjenjuje kao pomoćna terapija uz primjenu metformina i inzulin glargina.
The compounds of Set B may be prepared by one skilled in the art by the methods described above. 
Spojevi skupine B mogu pripremiti osobe iz struke primjenom postupaka koji su gore opisani.
Use of the compound or a salt thereof according to claim 7, for the manufacture of a pharmaceutical composition for preventing and/or treating EGFR T790M mutation positive cancer. 
Uporaba spoja ili njegove soli prema zahtjevu 7, naznačena time, da je za proizvodnju farmaceutskog sastava za prevenciju iili hječenje raka pozitivnog na mutaciju T790M od EGFR, 10.
A process for producing coloured glass in accordance with claim 12, comprising the following steps: 
Proces proizvodnje obojenog stakla, koji sadrži slijedeće korake;
The device of claim 1, wherein the motors of the sheaves are independently operated. 
Uređaj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da su rotacijski nosači (2) nezavisno upravljani.
The formulation of claim 1, wherein the polyalcohol is propylene glycol. The formulation of claim 7, wherein the propylene glycol is present in an amount of about 20.0% wt. 
Formulacija prema zahtjevu 1 ili 2, naznačena time, da navedeni polialkohol je propilen glikol, koji je poželjno prisutan u količini od 20.0% tež.
The present invention provides an immunogenic composition comprising an M72 related antigen, wherein the M72 related antigen comprises a sequence having at least 90% identity to SEQ ID No: 1, the pH of said composition is in the range 7.5 to 8.5, and the concentration of sodium chloride is 50 mM or lower. 
Imunogeni pripravak koji sadrži antigen povezan s M72, naznačen time što antigen povezan s M72 sadrži slijed koji je najmanje 90% istovjetan SEQ ID No: 1, pH navedenog pripravka je u rasponu od 7,0 do 9,0, a vodljivost pripravka je 5 mS/em ili manja.
The system according to claim 1, wherein each of the two suspension elements (29) is connected with its second end to a corresponding displacement device (24) and wherein the two suspension elements (29) are connected with their first ends together at a common mounting device (30). 
Sustav prema patentnom zahtjevu 1, naznačen time što su oba suspenzijska elementa (29) spojena sa svojim drugim krajem na korespondirajući uređaj za premještanje (24) pri čemu su suspenzijski elementi (29) međusobno povezani svojim prvim krajevima preko zajedničkog montažnog uređaja (30).
Conduit 14 and conduit 52 are not shown specifically in FIG. 6C, but would form fluid pathways from bottles 20 A and B and compressor 50, respectively, to a fluid outlet 210 from housing 200 . 
Cjevovod 14 i cjevovod 52 nisu posebno prikazani na slici 6C, ali će formirati kanale za fluide iz boca 20A 1 29D i iz kompresora 50, do izlaza 210 fluida iz kućišta 200.
The network according to claim 3, wherein metal nanoparticles having an average size between 1 and 100 nm are embedded in said network. 
Mreža u skladu s patentnim zahtjevom 3, naznačena time što su metalne nanočestice koje imaju prosječnu veličinu od 1 1 100 nm ugrađene u navedenu mrežu.
11 shows that while rapamycin induces nearly 80% platelet aggregation after 8 minutes, 42-O-(D-Fructosylcarbonyl)rapamycin does not exhibit a measurable effect on platelet aggregation in the same time. 
Slika 11 pokazuje da, dok rapamicin inducira gotovo 80% agregacije trombocita nakon 8 minuta, 42-O-(fruktozilkarbonil)rapamicin ne pokazuje mjerljiv učinak na agregaciju trombocita u istom vremenu.
A pharmaceutical composition comprising a therapeutically effective amount of the composition of any of claims 1-7 and a pharmaceutically acceptable carrier. 
Farmaceutski sastav, naznačen time, da sadrži terapeutski učinkovitu količinu sastava prema bilo kojem od patentnih zahtjeva 1-7 i farmaceutski prihvatljiv nosilac.
fraction A is conveyed to a chlorination reactor and fraction B to an oxychlorination reactor, in which reactors most of the ethylene present in fractions A and B is converted to 1,2-dichloroethane; 
frakcija A je prenesena u reaktor za klorinaciju, a frakcija B u reaktor za oksiklorinaciju, te se u tim reaktorima većina etilena koja se nalazi u frakcijama A i B, pretvara u 1,2-dikloroetan;
The method of claim 1, whereby a further mixing step is carried out, in which a further excipient is fed into the existing material stream. 
Postupak prema zahtjevu 11, gdje se provodi dodatni korak miješanja u kojem se dodaje dodatna pomoćna tvar u postojeći pokretni materijal.
optionally the oxytocin analogue of formula I so obtained is isolated and purified. 
tako dobiven oksitocinski analog formule I se opcijski izolira i pročisti.
removing a fraction of the supernatant from the culture; 
uklanjanje frakcije supernatanta iz kulture stanica;